title: Clinical outcomes and cardiac safety of continuous antiHer2 therapy in c-erbB2-positive metastatic breast cancer patients.
abstract: BACKGROUND
  To explore clinical outcomes and cardiac safety of continuous antiHer2 therapy.
  
  
  METHODS
  This retrospective study evaluates overall survival (OS), time to treatment failure (TTF), and cardiac safety of 80 consecutive Her2-positive metastatic breast cancer (MBC) patients that received ≥ 12 months of therapy with trastuzumab, followed by lapatinib-based or trastuzumab-based therapy.
  
  
  RESULTS
  All patients received trastuzumab as first antiHer2 therapy; 54% received lapatinib in the second or subsequent line. Median OS was 34 months (12-120 months). Median OS was 48 months in the subgroup of 43 patients who received lapatinib and 26 months in the 37 patients who did not. Median TTF was shorter for lapatinib. There were three cardiac events and trastuzumab-based chemotherapy (CT) was interrupted in one patient because left ventricular ejection fraction (LVEF) decreased to ≤ 40%.
  
  
  CONCLUSIONS
  Continuous antiHer2 therapy provides good clinical outcomes, especially in those patients who received lapatinib. Cardiac dysfunction was a rare event, reversible, associated to trastuzumab and not related to treatment duration.
authors.forename: Palma
authors.initials: P
authors.lastname: Fedele
authors.forename: Laura
authors.initials: L
authors.lastname: Orlando
authors.forename: Paola
authors.initials: P
authors.lastname: Schiavone
authors.forename: Mariangela
authors.initials: M
authors.lastname: Ciccarese
authors.forename: Rosa Chiara
authors.initials: RC
authors.lastname: Forcignanò
authors.forename: Nicola
authors.initials: N
authors.lastname: Calvani
authors.forename: Antonella
authors.initials: A
authors.lastname: Marino
authors.forename: Angelo
authors.initials: A
authors.lastname: Nacci
authors.forename: Francesco
authors.initials: F
authors.lastname: Sponziello
authors.forename: Enrica
authors.initials: E
authors.lastname: Mazzoni
authors.forename: Pietro
authors.initials: P
authors.lastname: Rizzo
authors.forename: Vito
authors.initials: V
authors.lastname: Lorusso
authors.forename: Saverio
authors.initials: S
authors.lastname: Cinieri
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D006321:Heart / Q000187:drug effects*; D006801:Humans; D000077341:Lapatinib; D008875:Middle Aged; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors*; D012189:Retrospective Studies; D000068878:Trastuzumab; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000077341:Lapatinib; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab
keywords: Cardiac safety,; Lapatinib,; Metastatic breast cancer,; Overall survival,; Trastuzumab